of this final rule with comment period, we are finalizing, with modification, our proposal that accreditors may not require as part of accreditation or otherwise encourage institutions to put in place diversity, equity, and inclusion programs that encourage unlawful discrimination on the basis of race or other violations of Federal law
Broader regulatory scrutiny of MEDVi as a platform is still relevant context for any thorough evaluation of its programs
Most insurance plans prefer to cover FDA-approved medications like Ozempic, which have proven safety and efficacy profiles
Waugh DJJ, Wilson C
Beyond Injections: How Oral GLP-1s Will Fit into Obesity Care This edition covers: The newest oral GLP-1s on the market Clinical differences between oral and injectable GLP-1s How a growing range of options is re-shaping health benefit strategies Last week, the FDA approved Lillys new oral GLP-1 medication, Foundayo (orforglipron), several months after the approval of Novo Nordisks Wegovy (semaglutide) pill the first oral GLP1 indicated both for weight management and for reducing cardiovascular risk in adults with obesity or overweight, and established heart disease